Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2026 06:27 ET | Source: Research and Markets

Construction Cybersecurity Research Report 2026: $18.41 Bn Market Opportunities, Trends, Competitive Analysis, Strategies, Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Construction Cybersecurity Market Report 2026" has been added to ResearchAndMarkets.com's offering. The construction cybersecurity market has...
January 20, 2026 07:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in...
January 08, 2026 08:30 ET | Source: Leslie’s Inc.

Leslie’s, Inc. Appoints John Hartmann to Board of Directors

PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Leslie's, Inc. ("Leslie's" or the “Company”; NASDAQ: LESL), the largest and most trusted direct-to-customer brand in the U.S. pool and spa care industry...
January 08, 2026 08:00 ET | Source: Navigator Medicines INC

Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials

FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1...
January 08, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics reports progress across its portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.
January 07, 2026 08:15 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and...
January 06, 2026 07:16 ET | Source: Bright Minds Biosciences

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3%...
January 05, 2026 07:00 ET | Source: Jade Biosciences

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Jade Biosciences Outlines Key 2026 Objectives and Strategy
January 05, 2026 06:30 ET | Source: Neumora Therapeutics, Inc.

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a...
December 23, 2025 06:00 ET | Source: Dianthus Therapeutics, Inc.

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B...